New hope for advanced cancer patients as experimental drug enters human testing.
NCT ID NCT06726369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug can shrink or control tumors. This is not a cure, but a step toward a possible new treatment option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, 100142, China
-
Chongqing University Cancer Hospital
NOT_YET_RECRUITINGChongqing, China
-
Fujian Provincial Cancer Hospital
NOT_YET_RECRUITINGFuzhou, China
-
Hubei Cancer Hospital
NOT_YET_RECRUITINGWuhan, China
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, 410031, China
-
Shanghai East Hospital
NOT_YET_RECRUITINGShanghai, China
-
West China Hospital of Sichuan University
NOT_YET_RECRUITINGChengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?